A single liver-sparing myotropic AAV ameliorates muscular dystrophy in humanized mice by base editing
Journal of Clinical Investigation · 02.11.2026 · 136 (21)
DOI: 10.1172/jci202378 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Investigation, online erschienen am 02.11.2026. Verfasst von Yu-Chung Pien und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Biology. Hauptthemen laut MEDLINE: Dependovirus, Muscular Dystrophy, Duchenne, Liver, Gene Editing. Die Arbeit nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NICHD NIH HHS, NIAMS NIH HHS, Foundation for the National Institutes of Health.
Abstract (Originalsprache)
Duchenne muscular dystrophy (DMD) is caused by mutations in the DMD gene, most of which are large exon deletions that result in loss of dystrophin protein. Adenine base editing (ABE) enables permanent gene correction by modifying splice sites to cause exon skipping and restoration of the DMD open reading frame. We previously demonstrated that adeno-associated virus 9–mediated (AAV9-mediated) delivery of adenine base editors allows efficient gene editing in mouse models of DMD. However, conventional AAV-based gene delivery approaches are complicated by their limited packaging capacity and high-dose-related toxicity. Here, we describe a single AAV vector encoding a compact adenine base editor, SlugABE8e, and a single-guide RNA, which enable efficient editing in a humanized DMD mouse model at a lower dose using the muscle-tropic MyoAAV4 capsid. Systemic MyoAAV4A delivery in juvenile DMD mice efficiently restored dystrophin expression in the heart and skeletal muscles. This molecular rescue was accompanied by reduced serum creatine kinase activity and diminished muscle pathology. A liver-detargeted MyoAAV4E-off capsid eliminated viral entry and editing in the liver. We also explored a high-fidelity base editor, SlugHF-ABE8e(V106W), which showed similar on-target and off-target editing to SlugABE8e. Together, these findings establish an all-in-one AAV strategy that efficiently mitigates DMD disease progression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Molecular Biology.
- Hamon Center for Regenerative Science and Medicine, and.
- Senator Paul D. Wellstone Muscular Dystrophy Specialized Research Center, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
- Grousbeck Gene Therapy Center, Schepens Eye Research Institute, and Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, Massachusetts, USA.
- The Broad Institute of Harvard and MIT, Cambridge, Massachusetts, USA.
- Cima Universidad de Navarra, Pamplona, Spain.
Förderung
- NICHD NIH HHS
- NIAMS NIH HHS
- Foundation for the National Institutes of Health
- Welch Foundation
- Fondation Leducq
- British Heart Foundation
Zitieren
APA
Pien, Y. C., Li, H., Bulliard, G., Liu, H., Durbacz, M. Z., Xu, Z., Chai, A. C., Chemello, F., Sanchez-Ortiz, E., Zabaleta, N., Vandenberghe, L. H., Liu, N., & Olson, E. N. (2026). A single liver-sparing myotropic AAV ameliorates muscular dystrophy in humanized mice by base editing. Journal of Clinical Investigation, 136(21). https://doi.org/10.1172/jci202378
Vancouver
Pien YC, Li H, Bulliard G, Liu H, Durbacz MZ, Xu Z, et al. A single liver-sparing myotropic AAV ameliorates muscular dystrophy in humanized mice by base editing. Journal of Clinical Investigation. 2026;136(21). doi:10.1172/jci202378
BibTeX
@article{Pien2026,
author = {Pien, Yu-Chung and Li, Hui and Bulliard, Gabrielle and Liu, Huachun and Durbacz, Mateusz Z and Xu, Zhisheng and Chai, Andreas C and Chemello, Francesco and Sanchez-Ortiz, Efrain and Zabaleta, Nerea and Vandenberghe, Luk H and Liu, Ning and Olson, Eric N},
title = {A single liver-sparing myotropic AAV ameliorates muscular dystrophy in humanized mice by base editing},
journal = {Journal of Clinical Investigation},
year = {2026},
volume = {136},
number = {21},
doi = {10.1172/jci202378}
}
EUVIMED